Ipilimumab-induced colitis: experience from a tertiary referral center

Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.

(2017) R. A. Ibrahim et al.   JOURNAL OF CLINICAL ONCOLOGY

Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies.

(2017) S. O'Day et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic review: colitis associated with anti-CTLA-4 therapy

(2015) A. Gupta et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

(2013) S. F. Slovin et al.   ANNALS OF ONCOLOGY

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma

(2012) Stephanie Andrews et al.   Cancer Management and Research

Guidelines for the management of inflammatory bowel disease in adults

(2011) C. Mowat et al.   GUT

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY